Table 2 Univariate analyses of risk factors for 2-year OS, LFS, NRM, and RI (AML, n = 63).

From: Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

 

n

OS (CI 95%)

LFS (CI 95%)

NRM (CI 95%)

RI (CI 95%)

Adverse cytogeneticsa

  not adverse

45

31.9% (18.4–46.3)

24.6% (12.9–38.4)

15.7% (6.8–27.9)

59.7% (42.9–73.1)

  adverse

18

21.7% (5.7–44.1)

16.3% (3.2–38.5)

17.2% (3.7–39.1)

66.5% (34.4–85.5)

 P value

 

0.56

0.62

0.6

0.68

Secondary AML

  de novo

52

25.3% (13.7–38.7)

20% (10–32.4)

19.7% (10–31.8)

60.3% (44.7–72.8)

  secondary AML

11

45.5% (16.7–70.7)

30.3% (5.9–60.4)

0%

69.7% (21.5–91.9)

 P value

 

0.2

0.3

0.1

0.57

Stage at HAPLO-SCT1

  active disease

26

7.7% (1.3–21.7)

7.7% (1.3–21.7)

15.4% (4.6–32)

76.9% (53.6–89.5)

  CR

36

44.7% (26.8–61.1)

31.4% (16.2–47.8)

17.4% (6.9–32)

51.2% (32.2–67.3)

 P value

 

0.008

0.026

0.65

0.059

Stage at HAPLO-SCT2

  active disease

42

18.5% (8–32.2)

15.9% (6.7–28.6)

12.2% (4.3–24.5)

72% (54.9–83.5)

  CR

21

52.2% (27.8–71.8)

35.5% (14.4–57.5)

24.6% (8.5–45)

39.9% (16.3–62.8)

 P value

 

0.047

0.043

0.09

0.003

Patient age (years)

  ≤44.8 (median)

32

24.3% (10.9–40.7)

19.5% (7.7–35.3)

12.5% (3.8–26.6)

68% (47.2–82)

  >44.8

31

32.9% (16–50.9)

24.8% (10.5–42.1)

20% (7.8–36.2)

55.2% (34.1–72)

 P value

 

0.2

0.27

0.67

0.23

Karnofsky performance score

  <90

29

27.6% (12.2–45.5)

25.3% (10.9–42.6)

21.5% (8.3–38.6)

53.3% (32.5–70.2)

  ≥90

29

35% (18–52.5)

23% (9.7–39.7)

13.8% (4.2–29)

63.2% (41.8–78.6)

 P value

 

0.3

0.22

0.63

0.57

Conditioning for HAPLO-SCT2

  MAC

24

35.2% (16.7–54.3)

30.8% (13.5–50)

17% (5–35)

52.2% (29.3–71)

  RIC

36

20% (7.7–36.5)

17.1% (6.7–31.5)

16.8% (6.7–30.9)

66.1% (46.9–79.7)

 P value

 

0.3

0.053

0.78

0.08

Interval from HAPLO-SCT1 to relapse (months)

  ≤8.74 (median)

32

9.9% (2.5–23.3)

9.4% (2.4–22.3)

15.6% (5.4–30.8)

75% (55–87.1)

  >8.74

31

49.3% (29–66.7)

35.5% (17.8–53.8)

16.4% (5.8–31.8)

48% (27.1–66.3)

 P value

 

0.001

0.001

0.71

0.008

Donor change for HAPLO-SCT2

  Yes

35

27% (12.7–43.5)

21.7% (9.4–37.2)

23.5% (10.7–39)

54.9% (35.7–70.5)

  No

21

35.7% (15.5–56.6)

24.5% (7.7–46.1)

4.8% (0.3–20.4)

70.7% (40.3–87.6)

 P value

 

0.76

0.5

0.052

0.35

Donor change for HAPLO-SCT2 in relapses ≥ 6 months after HAPLO-SCT1

  Yes

37

36.3% (22.1–50.6)

26.6% (14.9–39.9)

22% (11.6–34.6)

51.3% (36–64.7)

  No

12

35.1% (15.5–55.6)

24.2% (7.7–45.6)

8.7% (1.4–24.7)

67.1% (38–84.8)

 P value

 

0.56

0.83

0.16

0.39

  1. OS overall survival, LFS leukaemia-free survival, NRM non-relapse mortality, RI relapse incidence, MAC myeloablative conditioning, RIC reduced intensity conditioning, CR complete remission.
  2. aUnknown was considered as not adverse.
Back to article page